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Abstract
Introduction: We recently developed a chelating platform based on the macrocycle 1,4,7-
triazacyclononane with up to three five-membered azaheterocyclic arms for complexation of 
the PET nuclides gallium-68 and copper-64. The main objective of this study was to evaluate 
the stability and pharmacokinetics of 68Ga- and 64Cu-complexes of the bifunctional chelator 
NODIA-Me 1 covalently bound to a PSMA targeting vector in vivo. 
Methods: NODIA-Me 1 was conjugated to the PSMA targeting Glu-NH-CO-NH-Lys moiety 
to give the bioconjugate NODIA-Me-NaI-Ahx-PSMA 4. The stability of [68Ga]4 and [64Cu]4 
was assessed in vitro by serum stability studies. The PSMA binding affinity was determined 
in competitive cell experiments in LNCaP cells using 68Ga-PSMA-HBED-CC as radioligand. 
The stability and pharmacokinetics of [68Ga]4 and [64Cu]4 was evaluated by PET imaging 
and ex vivo biodistribution studies in mice bearing subcutaneous LNCaP tumors.
Results: In human serum, [68Ga]4 and [64Cu]4 remained intact to 85% (3 h) and 92% (24 h), 
respectively. Nature of the metal chelate influenced PSMA binding affinity with IC50 of 233 
± 10 nM for uncomplexed 4, 681 ± 7 nM for Cu-4 and 176 ± 10 nM for Ga-4. In animal 
studies, [68Ga]4 and [64Cu]4 revealed low uptake (≤1% IA g-1) in the majority of organs. 
Kidney uptake at 1 h p.i. was 6.28 ± 0.92% IA g-1 and 4.96 ± 0.79% IA g-1 and specific tumor 
uptake was 1.33 ± 0.46% IA g-1 and 2.15 ± 0.38% IA g-1 for [68Ga]4 and [64Cu]4, 
respectively. 
Conclusion: The bifunctional chelator NODIA-Me 1 was successfully conjugated to a PSMA 
targeting moiety. In small-animal PET imaging and ex vivo biodistribution studies, 68Ga- and 
64Cu-labelled conjugates specifically delineated PSMA-positive LNCaP tumors and exhibited 
rapid renal clearance from non-target tissues with no significant demetallation/transchelation 
in vivo. The results support further development of this novel chelating platform for 
production of 68Ga- and 64Cu-labelled radiopharmaceuticals.
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1. Introduction
Obtaining maximum information from positron emission tomography (PET) imaging relies 
on the development of target-specific radiotracers. Besides compounds labelled with the PET 
nuclides carbon-11 and fluorine-18, radiopharmaceuticals labelled with positron-emitting 
radiometals are an important part of ongoing research. In particular, the two radiometals 
gallium-68 and copper-64 have received increased attention in the development of new PET 
radiopharmaceuticals. One general advantage over carbon-11 and fluorine-18 is that labelling 
reactions using radiometals can typically be carried out in aqueous media and are therefore 
amenable to kit formulations. The interest in gallium-68 originates from its physical 
properties (t1/2 = 67.71 min, ß+ 89%, E(ß+)max = 1.9 MeV), which are suitable for use with 
targeting vectors possessing rapid pharmacokinetics such as radiotracers based on small 
molecules and peptides [1-4]. In contrast to carbon-11 and fluorine-18, the radiometal 
gallium-68 is generator produced and readily accessible without the need for an on-site 
cyclotron. More recently, a GMP-compliant pharmaceutical grade generator produced by 
Eckert & Ziegler has received marketing authorization. Other clinical grade gallium-68 
generators are in development, which will spur the continued use of 68Ga-based 
radiopharmaceuticals in the near future [5]. 
The cyclotron-produced radiometal copper-64 has also shown promise as both a 
suitable PET imaging and a therapeutic radionuclide due to its favorable decay characteristics 
(t1/2 = 12.7 h, ß+ 17.4%, E(ß+)max = 0.656 MeV; ß- 39%, E(ß-)max = 0.573 MeV) and 
commercial availability in large quantities with high specific activity [6-8]. The intermediate 
half-life of copper-64 allows visualization of processes at time points up to 48 h, which is 
ideal for developing radiopharmaceuticals that require longer circulation times to achieve 
optimal uptake. The half-life of copper-64 also allows central production and shipment. 
Furthermore, 64Cu-labelled radiopharmaceuticals may be used to provide pharmacokinetic 
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profiles of therapeutic radiotracers that are labelled with copper-67 (t1/2 = 61.5 h, ß- 100%, 
Emax = 0.121 MeV) as this isotope has promise in endoradiotherapy applications [9]. 
Radiolabelling of target-specific radiopharmaceuticals with a radiometal generally 
requires the use of a bifunctional chelator (BFC) that (1) forms kinetically stable complexes 
with the radiometal and (2) possesses a function for the covalent attachment of a target-
specific molecule. High kinetic and metabolic stability of the metal chelate is essential to 
avoid accumulation of radioactivity in background tissues that may result from degradation or 
transmetallation in vivo. However, introduction of a metal chelate into a biomolecule is a 
non-innocent modification. Chelates/metal complexes often have an impact on the biological 
properties of the radiopharmaceutical. The use of different radiometals with the same BFC 
can alter binding affinities as illustrated by reported studies on various gallium and yttrium 
labelled somatostatin analogs such as DOTA-[Tyr3]-octreotate and DOTA-octreotide [10]. 
Variation of the metal chelate by using different BFCs with the same radiometal can also 
result in altered pharmacokinetic profiles [11-12]. Interestingly, the influence of the metal 
chelate is not limited to radiotracers based on small molecules or peptides. For example, the 
biodistribution profiles of 64Cu-labelled antibody fragments as well as full antibody 
conjugates can also be influenced by the nature of the metal chelate [13-14]. Evidently the 
important role that chemical structure has on the biological performance of a radiotracer 
demands continued development and optimization of new BFCs. The dependency of 
radiotracer performance on the chemical structure also presents an opportunity for 
radiochemists to tune the pharmacokinetics. Radiotracer design incorporates control over the 
metal complex properties such as overall charge, lipophilicity and size as indispensable 
handles for optimizing target-specific binding and distribution in vivo.
Numerous BFCs have been developed for both gallium-68 and copper-64 (Scheme 1), 
such as NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), NODAGA (1,4,7-
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triazacyclononane-1-glutaric acid-4,7-diacetic acid) [15-18] [1, 11, 19-21], TRAP (1,4,7-
triazacyclononane-1,4,7-tris[methyl(2-carboxyethyl)phosphinic acid) [22-24], PCTA 
(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid) [25-27], and 
rigid cage-like sarcophagine type ligands such as diamsar [3, 28-32]. The most prominent 
BFC for gallium-68 is the ligand DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid [6], while copper-specific ligands include CB-TE2A (2,2'-(1,4,8,11-
tetraazabicyclo[6.6.2]hexadecane-4,11-diyl)diacetic acid) [28, 33-38], and bispidines [39-41]. 
For a more comprehensive overview, the reader is referred to recent reviews [6, 42-45].
The clinical success of 68Ga-labelled PSMA-HBED-CC (also known as DKFZ-
PSMA-11) represents an archetypal example of a system where the nature of the metal 
chelate forms an integral part of the radiotracer’s binding mode. The aromatic rings of the 
[68Ga]Ga-HBED-CC chelate form a key element for docking hydrophobic patches near the 
binding pocket of the target protein prostate-specific membrane antigen (PSMA) [46]. PSMA 
is an attractive molecular target for the diagnosis due to its upregulation in primary and 
metastatic prostate cancer [47-48]. The PSMA pocket is comprised of two sub-pockets with 
one surface-exposed highly positively charged pharmacophore region containing two Zn2+ 
ions, and a second buried hydrophobic non-pharmacophore sub-pocket [49-50]. While the 
urea motif of PSMA-HBED-CC binds to the pharmacophore region, the BFC HBED-CC 
interacts advantageously with the lipophilic part of the PSMA pocket [46, 51]. In case of 
traditional macrocyclic BFCs like DOTA, which lack aromatic rings, lipophilic substituents 
were consequently introduced into the linker region in order to mimic the proven additional 
biologic interactions of the chelator HBED-CC [52-56]. 
We recently described a chelating platform based on the macrocycle 1,4,7-
triazacyclononane (TACN) with additional five-membered azaheterocyclic arms including 
imidazole, methylimidazole and thiazole residues [57]. These ligands are characterized by 
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their excellent complexation properties for radioactive, divalent copper cations. They label 
instantaneously with [64Cu]CuCl2 under very mild conditions in the pH range of 4 – 8 with 
high molar activities of 120 – 180 MBq nmol-1. Experiments showed that corresponding 
methylimidazole-type ligands (e.g. NODIA-Me in Scheme 1) that incorporate borderline 
azaheterocyclic N donors according to the HSAB (hard and soft acids and bases) principle 
form rigid and stable Ga3+ complexes allowing their application also with the PET-nuclide 
gallium-68 [58]. This study reports the in vitro and in vivo evaluation of the BFC NODIA-Me 
(2-(4,7-bis((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)acetic acid) 1 labelled 
with gallium-68 and copper-64 in combination with the glutamate-urea-lysine moiety for 
targeting PSMA. The aim of this study was to demonstrate that NODIA-Me is suitable for 
future radiopharmaceutical development.
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2. Materials and Methods
2.1. General
Chemicals and solvents were purchased from Sigma-Aldrich and TCI Europe, and used as 
received. The precursor Glu-NH-CO-NH-Lys(Ahx)-(tBu)3 ester was purchased from ABX 
(Radeberg, Germany). Fmoc-3-(2-naphthyl)-L-alanine was obtained from IRIS Biotech 
(Marktredwitz, Germany). The bifunctional chelator NODIA-Me (2-(4,7-bis((1-methyl-1H-
imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)acetic acid) 1 was prepared as previously 
described [58]. The radiotracer [68Ga]Ga-PSMA-HBED-CC was prepared as previously 
described [59]. Low resolution electrospray ionisation mass spectrometry (LR-ESI(+)-MS) 
was performed on a PerkinElmer Flexar SQ 300 MS Detector. High resolution mass 
spectrometry (HR-ESI(+)-MS) was performed on a Thermo Scientific Exactive mass 
spectrometer. 1H and 13C NMR spectra were measured in D2O at room temperature using a 
Bruker Avance III HD 500MHz NMR spectrometer (Rheinstetten, Germany). Chemical 
shifts are given in parts per million (ppm) and are reported relative to 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS). Coupling constants are reported in hertz (Hz). The 
multiplicity of the NMR signals is described as follows: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet. Radiolabelling with [68Ga]GaCl3 was accomplished using a fully 
automated synthesis module (Pharmtracer, Eckert & Ziegler, Berlin, Germany) with an 
IGG100 generator (Eckert & Ziegler, Berlin, Germany). [64Cu]CuCl2 was purchased from the 
Department of Preclinical Imaging and Radiopharmacy of the Eberhard-Karls-University 
(Tübingen, Germany). [64Cu]CuCl2 was produced via the 64Ni(p,n)64Cu route. The 
corresponding molar activity was 300–400 MBq nmol-1 (18 h EOB). High performance liquid 
chromatography (HPLC) was conducted on an Agilent 1260 Infinity System equipped with 
an Agilent 1200 DAD UV detector (UV detection at 220 nm) and a gamma-radiation detector 
(Ramona, Raytest GmbH, Straubenhardt, Germany) in series. A Phenomenex Jupiter Proteo 
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(250 × 4.60 mm) column was used for analytical HPLC. The solvent system was A = H2O 
(0.1% TFA) and B = acetonitrile (0.1% TFA). The gradient was 0–1 min 5% B, 1–20 min 5–
40% B at a flow rate of 1 mL min-1. Semi-preparative HPLC was performed on a Knauer 
Smartline 1000 HPLC system in combination with a Macherey Nagel VP 250/21 Nucleosil 
120-5 C18 column. Conditions A were 0–40 min 5–60% B at a flow rate of 12 mL min-1. 
Conditions B were 0–25 min 5–95% B at a flow rate of 12 mL min-1. Samples were 
lyophilized using a Christ Alpha 1-2 LD plus lyophilizer. All instruments measuring 
radioactivity were calibrated and maintained in accordance with previously reported routine 
quality-control procedures [60]. Radioactivity was measured using an Activimeter ISOMED 
2010 (Nuklear-Medizintechnik, Dresden, Germany). For accurate quantification of 
radioactivity, experimental samples were counted for 1 min on a calibrated PerkinElmer 
(Waltham, MA) 2480 Automatic Wizard Gamma Counter by using a dynamic energy 
window of 400–600 keV for gallium-68 and copper-64 (511 keV emission). A Thermo Fisher 
Heraeus Fresco 21 centrifuge was used for centrifugation.
2.2. Bioconjugate Synthesis
2.2.1. Glu-NH-CO-NH-Lys(Ahx-NaI)-(tBu)3 ester (2)
Fmoc-L-2NaI-OH (Fmoc-3-(2-naphthyl)-L-alanine) (16.6 mg, 0.038 mmol), HATU (1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide 
hexafluorophosphate) (14.5 mg, 0.038 mmol) and DIPEA (N,N-diisopropylethylamine) (9.8 
mg, 14 µL, 0.076 mmol) were mixed in 500 µL anhydrous N,N-dimethylformamide (DMF) 
and allowed to stir for 1 h at r.t.. Then, Glu-NH-CO-NH-Lys(Ahx)-(tBu)3 (20.7 mg, 0.034 
mmol) in 100 µL DMF was added and stirring was continued for additional 16 h. The solvent 
was removed by rotary evaporation and the residue treated with 20% piperidine/DMF for 30 
min at r.t.. After removal of the solvent, the residue was taken up in water/acetonitrile (50:50 
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v/v) with 0.1 % trifluoroacetic acid (TFA) and purified by semi-preparative HPLC. Fractions 
containing the product were combined and lyophilized to give compound 2 as white powder 
(26.3 mg, 0.033 mmol, 97%). LR-ESI-MS calcd m/z for C43H68N5O9 (M + H): 798.5, found: 
799.1. HR-ESI-MS calcd m/z for C43H68N5O9 (M + H): 798.5012, found: 798.5007. RP-
HPLC (semi-preparative, conditions A): tR = 44 min.
2.2.2. NODIA-Me-NaI-Ahx-PSMA-(tBu)3 ester (3)
NODIA-Me (13.6 mg, 0.036 mmol), HATU (15.2 mg, 0.040 mmol) and DIPEA (10.3 mg, 14 
µL, 0.080 mmol) were mixed in 500 µL anhydrous DMF and allowed to stir for 30 min at r.t. 
Then, compound 2 (26.3 mg, 0.033 mmol) in 100 µL DMF was added and stirring was 
continued for additional 16 h. The solvent was removed by rotary evaporation and the residue 
was taken up in water/acetonitrile (50:50 v/v) with 0.1 % TFA and purified by semi-
preparative HPLC. Fractions containing the product were combined and the solvent removed 
by rotary evaporation to give compound 3 as colorless solid (26.5 mg, 0.023 mmol, 70%). 
LR-ESI-MS calcd m/z for C61H95N12O10 (M + H): 1155.7, found: 1156.3. HR-ESI-MS calcd 
m/z for C61H95N12O10 (M + H): 1155.7289, found: 1155.7301. RP-HPLC (semi-preparative, 
conditions B): tR = 25 min.
2.2.3. NODIA-Me-NaI-Ahx-PSMA (4)
Compound 3 (26.5 mg, 0.023 mmol) was dissolved in 1 mL 5 M hydrochloric acid and 
allowed to stir for 16 h at room temperature. The reaction mixture was concentrated by rotary 
evaporation to a volume of 1 mL and further purified by semi-preparative HPLC to give 
NODIA-Me-NaI-Ahx-PSMA ((4S,18S,22S)-1-(4,7-bis((1-methyl-1H-imidazol-2-yl)methyl)-
1,4,7-triazonan-1-yl)-4-(naphthalen-2-ylmethyl)-2,5,12,20-tetraoxo-3,6,13,19,21-
pentaazatetracosane-18,22,24-tricarboxylic acid) 4 as colorless powder after lyophilization 
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(20.6 mg, 0.021 mmol, 91%). 1H-NMR (D2O, pD ≤ 2): δ = 7.79 – 7.73 (4H, m), 7.48 – 7.45 
(4H, m), 7.42 (1H, d, J = 1.7), 7.33 (2H, s), 4.89 (1H, dd, J = 10.7, 4.7), 4.21 (3H, m), 4.06 – 
3.95 (3H, m), 3.69 (3H, s), 3.67 (3H, s), 3.47 (2H, m), 3.36 – 3.28 (4H, m), 3.12 – 2.94 (7H, 
m), 2.80 (1H, m), 2.67 (1H, d, J = 16), 2.53 (1H, m), 2.54 (4H, m), 2.43 (1H, m), 2.12 (3H, 
m), 2.01 (1H, m), 1.92 (1H, m), 1.67 (1H, m), 1.55 (1H, m), 1.49 – 1.38 (6H, m), 1.26 (2H, 
m), 1.15 (2H, m). 13C-NMR (D2O, pD ≤ 2): δ = 177.2, 176,7, 176.2, 171.5, 165.0, 163.0 (q, 
TFA), 159.2, 142.6, 134.8, 133.0, 132.0, 128.2, 128.1, 127.9, 127.4, 127.2, 126.8, 126.3, 
124.2, 124.1, 118.8, 118.6, 116.3 (q, TFA), 56.4, 55.9, 53.3, 53.2, 52.6, 51.6, 50.0, 48.4, 47.8, 
47.0, 45.3, 39.3, 39.0, 35.6, 34.4, 30.5, 30.0, 28.0, 27.8, 26.3, 25.4, 24.9, 22.3. LR-ESI-MS 
calcd m/z for C49H71N12O10 (M + H): 987.5, found: 987.7. HR-ESI-MS calcd m/z for 
C49H71N12O10 (M + H): 987.5411, found: 987.5399. RP-HPLC (semi-preparative, conditions 
B): tR = 14 min; RP-HPLC (analytical, UV: 220 nm): tR = 15:20 min.
2.3. Preparation of non-radioactive references
For each reference compound, the bioconjugate 4 (500 µg, 0.51 µmol) in 250 µL H2O was 
mixed with 250 µL of metal stock solutions containing 1.5 equivalents of the corresponding 
metal salt (CuCl2⋅2 H2O, Ga(NO3)3 hydrate) and heated at 95 °C for 15 min. After cooling to 
r.t., the complexes were purified using C18 Sep Pak cartridges, which were preconditioned 
with EtOH and H2O (5 mL each). After loading, the cartridge was washed with H2O (2 mL) 
and the product was eluted off using EtOH:H2O (50:50 v/v; 2mL). After evaporation of EtOH 
at ambient temperature, samples were lyophilized to give Cu-4 (479 µg, 0.46 µmol, 90%) and 
Ga-4 (461 µg, 0.44 µmol, 86%). HR-ESI-MS of Cu-4 calcd m/z for C49H69CuN12O10+ (M – 
H): 1048.4550, found: 1048.4551. RP-HPLC of Cu-4 (analytical, UV: 220 nm): tR = 17:42 
min. HR-ESI-MS of Ga-4 calcd m/z for C49H68GaN12O10+ (M – 2H): 1053.4432, found: 
1053.4426. RP-HPLC of Ga-4 (analytical, UV: 220 nm): tR = 15:33 min.
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2.4. Radiolabelling
2.4.1. Radiosynthesis of [68Ga]Ga-NODIA-Me-NaI-Ahx-PSMA ([68Ga]4)
68Ga radiolabelling was accomplished by using the Modular-Lab PharmTracer automated 
synthesis module (Eckert&Ziegler, Berlin, Germany) as previously described [58]. The 
reaction vial contained 20 µg of 4 in a mixture of 400 µL sodium acetate buffer (pH 4.5) and 
2 mL water. Radiolabelling was performed at 95°C for 10 min. The radiochemical purity 
(RCP) was >98% and the decay corrected radiochemical yield (RCY) was >98%. The mean 
molar activity was Am = 20.2 ± 2.3 MBq nmol-1 (n = 10). RP-HPLC (analytical, radioactivity 
detector): tR ([68Ga]4) = 15:50 min. 
2.4.2. Radiosynthesis of [64Cu]Cu-NODIA-Me-NaI-Ahx-PSMA ([64Cu]4)
Radiolabelling with [64Cu]CuCl2 was accomplished by dissolving 6 µg (6 nmol) of 4 in 200 
µL ammonium acetate (0.1 M, pH 8.2) followed the addition of ~120 MBq [64Cu]CuCl2 in 
0.1 M HCl. The solution was then incubated for 15 min at r.t. The RCP was >99% and the 
decay corrected RCY was >99%. The mean molar activity was Am = 20.5 ± 1.8 MBq nmol-1 
(n = 5). RP-HPLC (analytical, radioactivity detector): tR ([64Cu]4) = 17:43 min.
2.5. Lipophilicity (log Doct/PBS) measurements
For log Doct/PBS measurements, 1–2 MBq of [68Ga]4, [64Cu]4 and [68Ga]Ga-PSMA-HBED-CC 
(20 µL) were added to a pre-saturated mixture of phosphate buffered saline pH 7.4 (PBS) 
(480 µL) and octanol (500 µL). Samples were shaken for 30 min at room temperature, 
centrifuged at 21,100 g for 5 min and 100 µL of each phase were counted using a Packard 
Cobra gamma counter. Experiments were performed in triplicate.
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2.6. Serum stability measurements
For each experiment, 5–10 MBq (50 µL) of [68Ga]4 and [64Cu]4 were added to human serum 
(500 µL, human male AB plasma, Sigma-Aldrich), which was pre-equilibrated at 37 °C in a 
cell incubator for 1 h. Samples were vortexed briefly and stored at 37 °C in a cell incubator. 
At selected time points, 100 µL aliquots were taken from the serum solution and serum 
proteins removed by centrifugation using centrifuge tubes (molecular weight cutoff 30 kDa) 
at 4,000 g for 5 min at 4 °C. 100 µL PBS were added to the filter followed by an additional 
centrifugation step. For determination of protein bound fraction, the filters and the filtrates 
were transferred into plastic tubes, and samples were counted using a Packard Cobra gamma 
counter. A sample of the filtrate was kept on ice until HPLC analysis. The percentage of 
intact [68Ga]4 and [64Cu]4 was calculated from the HPLC chromatograms. All experiments 
were performed in triplicate.
2.7. Cell culture
PSMA-positive LNCaP cells (ATCC, Manassas, VA, USA) were cultured at 37 °C in a 5% 
CO2 atmosphere (RPMI Medium 1640 GlutaMAX containing 10% FBS, 1% 100 U mL-1 
penicillin and 100 μg mL-1 streptomycin, 1% sodium-pyruvate 1 mM, 1% L-glutamin 2 mM). 
2.8. Competitive binding assay
The binding affinity of the bioconjugate 4 and the corresponding metallated compounds Ga-4 
and Cu-4 was determined using a cell-based competitive binding assay with 68Ga-labelled 
PSMA-HBED-CC (PSMA-DKFZ-11) according to the literature with minor modifications 
[61]. Briefly, each compound at different concentrations (0 – 5000 nM) was incubated for 1 h 
at 37 °C with 0.15 nM [68Ga]Ga-PSMA-HBED-CC together with 2×105 LNCaP cells per 
well. After incubation, cells were washed three times with ice-cold PBS and cell-associated 
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activity recovered by addition of 1 M NaOH. Radioactivity was measured by a gamma 
counter and data fitted using non-linear regression (GraphPad Prism). Experiments were 
performed two times in triplicate. 
2.9. Small-animal PET imaging
All animal experiments complied with the current laws of the Federal Republic of Germany 
and were conducted according to German Animal welfare guidelines. Normal female athymic 
Balb/c nude mice (17–20 g, 4–6 weeks old) were obtained from Janvier SAS (St. Berthevin 
Cedex, France). Mice were provided with food and water ad libitum. LNCaP tumors were 
induced on the shoulder by sub-cutaneous injection of 5×106 cells in a 100 μL cell suspension 
of a 1:1 v/v mixture of media with reconstituted basement membrane (GFR BD MatrigelTM, 
Corning BV, Amsterdam, Holland). After an average of 4 weeks, tumor size reached ~200 – 
300 mg and the animals were used for PET imaging studies. 
For PET imaging studies, mice were injected with 100 µL sterile filtered phosphate 
buffered saline formulations pH 7.4 of [64Cu]4 (6–8 MBq) or [68Ga]4 (18–23 MBq) by 
intravenous tail-vein injection and anesthetized with isoflurane (2–4% in air). PET Imaging 
was performed on a Focus 120 microPET scanner at 30 min, 1 h, 2 h and 3 h post-injection 
(p.i.). For copper-64, additional scans at 24 h p.i. were performed. Data were acquired for 10, 
15 or 60 min in list mode. Reconstruction was performed using unweighted OSEM2D. Image 
analysis was performed using AMIDE. Image counts per second per voxel (cps/voxel) were 
calibrated to activity concentrations (Bq mL-1) by measuring a 3.5 cm cylinder phantom filled 
with a known concentration of radioactivity. Time-activity curves (TACs) were constructed 
by manually drawing regions of interest (ROI) in the tumor, liver and the kidneys. All ROIs 
were then copied on each of the frames, and time-activity curves of the ROI mean values 
were generated. 
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Competitive inhibition (blocking) studies were also performed in vivo and measured 
using static PET imaging to investigate the specificity of the radiotracers for PSMA. As a 
blocking agent, non-radiolabelled 2-(phosphonomethyl)pentane-1,5-dioic acid (PMPA; 20 
nmol mouse-1) was co-injected with the radiotracers (n = 3) [62].
2.10. Ex vivo biodistribution
For each compound, a total of five animals were injected with [64Cu]4 (6–8 MBq) or [68Ga]4 
(18–23 MBq) in 100 µL sterile filtered phosphate buffered saline via a tail vein. At 60 min 
p.i., animals were sacrificed by isoflurane anesthesia. Organs of interest were dissected, 
weighed and assayed for radioactivity in a gamma counter. The percent injected activity per 
gram (%IA g-1) for each tissue was calculated by comparison of the tissue counts to a 
standard sample prepared from the injection solution. Specificity of the radiotracers for 
PSMA was determined by co-injection of PMPA (20 nmol mouse-1) [62].
3. Results and discussion
3.1. Bioconjugate synthesis
Our previously described triply substituted ligands lack a functionality for the covalent 
conjugation of biologically active targeting vectors [57]. For this reason, we developed the 
BFC NODIA-Me 1, in which we replaced one methylimidazole arm with an acetic acid group 
(Scheme 2) [58]. This acetic acid group serves as site for the attachment of appropriate 
targeting vectors via peptide bond formation. The glutamate-urea-lysine (Glu-NH-CO-NH-
Lys) structural motif is a well-known building block for the development of potent PSMA 
inhibitors [63-64]. Besides interactions of the urea and the carboxylic groups with the Zn2+ 
active site of the PSMA binding pocket, there are also lipophilic interactions with an 
accessible hydrophobic pocket [63, 65]. Therefore, a lipophilic naphthyl-alanine spacer was 
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introduced via standard Fmoc chemistry to the commercially available precursor Glu-NH-
CO-NH-Lys(Ahx)-tBu3 ester to obtain the intermediate 2 in 97% yield (Scheme 2). 
Conjugation of NODIA-Me 1 was accomplished using HATU as coupling reagent to give 
compound 3 in 70% yield. Cleavage of the tBu-esters was accomplished by reaction of 3 in 5 
M hydrochloric acid for 16 h to give the final PSMA-bioconjugate 4 in 61% overall yield. 
The identity and purity of compound 4 (>98%) was determined by NMR spectroscopy, mass 
spectrometry and analytical RP-HPLC. Corresponding data are given in the Supporting 
Information. 
3.2. Radiochemistry
Radiosynthesis of [64Cu]4 was accomplished by mixing the bioconjugate 4 with the 
appropriate radioactivity amount of [64Cu]CuCl2 in ammonium acetate (pH 8.2) followed by 
incubation for 15 min at ambient temperatures. These mild conditions concur with the results 
obtained in previous 64Cu-labelling experiments of our ligands bearing three azaheterocyclic 
arms [57]. The RCP and the decay corrected RCY for [64Cu]4 were both determined to be 
>98%. 
Radiosynthesis of [68Ga]4 was performed in an automated, GMP-compliant process by 
heating compound 4 with [68Ga]GaCl3(aq.) at 95 °C for 10 min [58]. The RCP and the decay 
corrected RCY for [68Ga]4 were measured to >98% and for both radiometals molar activities 
of ~20 MBq nmol-1 were obtained. 
3.3. Lipophilicity
The log Doct/PBS values of [68Ga]4 and [64Cu]4 were measured in an octanol-phosphate 
buffered saline system (Table 1). Compounds are highly hydrophilic with log Doct/PBS values 
of -4.27 ± 0.08 and -3.99 ± 0.05 for [68Ga]4 and [64Cu]4, respectively. The order of 
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lipophilicity was corroborated chromatographically by RP-HPLC (Table 1). The lipophilicity 
of both compounds is comparable to [68Ga]Ga-PSMA-HBED-CC with log Doct/PBS = -4.06 ± 
0.10. 
We recently showed that the remaining coordination site of the gallium NODIA-Me 
complex can be occupied by monodentate ligands such as hydroxide or chloride [58]. The 
NODIA-Me complex charge can thus be estimated to +2 for [68Ga]4 and [64Cu]4. The 
deprotonated carboxylic acid functions of the Glu-NH-CO-NH-Lys PSMA-binding motif 
provide a 3-fold negative charge resulting in an estimated overall charge of both [68Ga]4 and 
[64Cu]4 of -1. In contrast, the PSMA-targeting reference ligand [68Ga]Ga-PSMA-HBED-CC 
possesses an estimated overall charge of -5 (-1 for the hexadentate N2O4-complex to Ga(III) 
with two carboxylates and two phenolates of the HBED-CC, -1 for the free terminal 
carboxyethyl-group of HBED-CC, and -3 for deprotonated carboxylic acid functions of the 
Glu-NH-CO-NH-Lys PSMA-binding motif) [66-68]. Despite the lower overall charge of 
[68Ga]4 and [64Cu]4 at physiological pH, the total number of charges is comparable to 
[68Ga]Ga-PSMA-HBED-CC. Furthermore, the positively charged NODIA-Me metal chelates 
result in a zwitterionic nature of the [68Ga]4 and [64Cu]4 PSMA-targeting probes. 
3.4. In vitro studies
3.4.1. Serum stability studies 
The stability of [68Ga]4 and [64Cu]4 was assessed in vitro by incubation at 37°C in human 
serum. For [68Ga]4, the amount of intact compound decreased from 94 ± 2% at 1 h to 85 ± 
3% after 4 h incubation time. The major metabolite of [68Ga]4 eluted after the dead volume of 
the system, consistent with the retention time of “free” gallium-68 and/or [68Ga]1. The 64Cu-
labelled conjugate [64Cu]4 was found to be more stable with 92 ± 2% intact tracer after 24 h 
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incubation. The protein associated fractions of [68Ga]4 and [64Cu]4 in the serum stability 
studies were determined to 48 ± 5% and 29 ± 2%, respectively. The protein bound fractions 
of [68Ga]4 and [64Cu]4 compare well to that of [68Ga]Ga-PSMA-HBED-CC, which was 
determined to 35 ± 3%. Finally, exchange of monodentate ligands such as chloride or 
hydroxide coordinated to the metal center, as reported previously, was not observed for 
[68Ga]4 [58]. 
3.4.2. Competitive binding assay
The binding affinities of 4, Ga-4 and Cu-4 were determined in a competitive binding assay on 
LNCaP cells using [68Ga]Ga-PSMA-HBED-CC as radioligand, which yielded IC50-values of 
233 ± 10 nM, 176 ± 10 nM and 681 ± 7 nM (Table 1). The IC50-values were converted to Ki-
values using the Cheng-Prusoff equation [69] and the reported Kd value for [68Ga]Ga-PSMA-
HBED-CC of 2.9 ± 0.6 nM [55]. With Ki values of 222 nM, 167 nM, and 648 nM, 
respectively, the NODIA-Me based PSMA-targeting ligands 4, Ga-4, and Cu-4 revealed 
substantially lower PSMA-binding affinities than [68Ga]Ga-PSMA-HBED-CC. Clearly, the 
size and charge of the metal chelating unit as well differences in the linker region have a 
major impact on the PSMA-binding affinity of the whole construct. 
Different from HBED-CC, the BFC NODIA-Me 1 does not possess any charge 
compensating donor groups and, consequently, forms metal complexes with Cu2+ and Ga3+ 
that have a positive overall charge. Under physiological conditions, the compounds [68Ga]4 
and [64Cu]4 presumably possess an estimated overall charge of -1. Even if no metal cation is 
coordinated to 4, the NODIA-Me chelating moiety is partially protonated at physiologic pH 
as the pKa values for the TACN amino groups are 7.0 and 11.3 and the pKa value of 
imidazole is 7.0 [70]. This partial protonation of the metal binding moiety of uncomplexed 4 
at physiological pH seems to translate to a PSMA binding affinity comparable to Ga-4. 
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Even though other factors cannot be excluded such as differences in the competition 
assay (different radioligand), the rather large charge difference between our NODIA-Me 
based PSMA-targeting probes and [68Ga]Ga-PSMA-HBED-CC may be the primary reason 
for their lower affinity. Indeed, recent studies by Babich and coworkers on 99mTc(CO3)-
labeled PSMA inhibitors containing functionalized imidazole rings have shown that charge 
has a major impact on binding affinity [71-72]. In a series of probes based on the Glu-NH-
CO-NH-Lys PSMA-binding motif and single amino acid chelate (SAAC) systems containing 
substituted di-imidazoles, increasing derivatization of the imidazole rings with negatively 
charged carboxylic acid functional groups resulted in significantly improved affinity for 
PSMA [71]. Building on these findings, addition of carboxylate groups to our NODIA-Me 
chelating platform may pave the way to a second generation of PSMA-targeting probes with 
higher affinity. 
Interestingly, however, the PSMA binding affinity of [64Cu]4 is almost 4-times lower 
than that of [68Ga]4 (both potentially having an overall charge of -1), suggesting that binding 
affinity of the probes is not a simple function of complex charge, but instead results from an 
interplay of several factors. Similar to our findings, the 64Cu-complex of the recently reported 
PSMA-targeting probe (R)-NODAGA-Phe-Phe-D-Lys(suberoyl)-Lys-urea-Glu (CC34) 
showed a higher Kd-value than its 68Ga-labeled counterpart [55].
3.5. In vivo studies
The aim of this study was to demonstrate the radiochemical scope and utility of the BFC 
NODIA-Me 1 for radiopharmaceutical design. Therefore, the stability and pharmacokinetic 
profiles of the 68Ga- and 64Cu-labelled PSMA conjugate 4 were assessed in vivo. The 
distribution and targeting of [68Ga]4 and [64Cu]4 in mice bearing subcutaneous PSMA-
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
Page 20
positive LNCaP tumors was measured by small-animal PET imaging and ex vivo 
biodistribution studies. 
3.5.1. Small-animal PET imaging
The pharmacokinetics of [68Ga]4 and [64Cu]4 were assessed by small-animal PET imaging of 
nude mice bearing LNCaP xenografts at 30 min, 1, 2 and 3 h post injection (p.i.) as well as 
after 24 h for [64Cu]4. Corresponding maximum intensity projections (MIPs) for [68Ga]4 and 
[64Cu]4 at 1 h p.i. are given in Figure 1. In addition, volume-of-interest (VOI) analysis was 
performed for both compounds on the LNCaP tumor, liver and kidneys (Figure 2). 
The distribution of radiotracers differs from each other with [64Cu]4 exhibiting a slightly 
higher uptake than [68Ga]4 in the majority of organs, which is potentially a consequence of its 
higher lipophilicity compared to [68Ga]4 (Table 1). Overall, uptake of both compounds in 
background organs was low due to their rapid blood pool clearance and renal excretion. Both 
conjugates [68Ga]4 and [64Cu]4 showed specific accumulation in PSMA positive LNCaP 
tumors (Figure 2A+C). Tumor uptake peaked at 30 min p.i. with 0.92% and 1.53% injected 
activity per gram (% IA g-1) for [68Ga]4 and [64Cu]4, respectively. A slow washout from the 
LNCaP tumors occurred for both compounds declining from 0.75% IA g-1 at 1 h p.i. to 0.41% 
IA g-1 at 3 h p.i. for [68Ga]4. The conjugate [64Cu]4 exhibited a slower washout than [68Ga]4 
with 1.14% IA g-1 at 1 h p.i. decreasing to 0.88% IA g-1 at 3 h p.i. and a prolonged retention 
with 0.39% IA g-1 still present in the tumor after 24 h. Compared to 68Ga-PSMA-HBEC-CC 
with a tumor uptake of ~3.5% IA g-1 at 1 h p.i. in similar PET-imaging studies [46], the tumor 
uptake of [68Ga]4 and [64Cu]4 in our studies at the same time point (1 h p.i.) was lower.  
However, tumor uptake is known to be dependent on the PSMA expression level of the 
specific batch of LNCaP-tumors and the total amount of the radioligand injected (~1 nmol of 
radioligand / mouse in our study), e.g., tumor uptake values in the report of Eder et al. [46] 
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were ~3.5% IA g-1 in their PET study (~0.5 nmol / mouse) compared to 7.70 ± 1.45% IA g-1 
in their ex vivo biodistribution study (0.1 – 0.2 nmol / mouse), while others even reported 
values of 15.8 ± 1.4% IA g-1 for an ex vivo biodistribution study with 10 pmol per mouse 
[55]. Specific uptake of [68Ga]4 and [64Cu]4 was demonstrated by blockade of PSMA using 
co-administration of PMPA. Blocking experiments resulted in a statistically significant 
reduction of tumor uptake (P < 0.05 over all time points) (Figure 2B + D). 
Liver uptake was very low for [68Ga]4 with 0.37% IA g-1 at 30 min p.i. reaching 
essentially background levels at 3 h p.i. (Figure 2A). For [64Cu]4, uptake peaked at 30 min 
p.i. with 1.31% IA g-1 and then plateaued at ~0.7–1.0% IA g-1 up to 24 h (Figure 2C). At all 
time points studied, the liver uptake of [64Cu]4 was slightly higher than that of [68Ga]4, which 
might be attributed to differences in lipophilicity (Table 1) or, alternatively, suggest 
instability of [64Cu]4 and superoxide dismutase (SOD1) dependent transchelation [73]. 
Importantly, however, the liver uptake of about 1.0% IA g-1 for [64Cu]4 is comparable to the 
liver uptake of the best candidates identified in an extensive study directed towards the 
development of novel 64Cu-labeled PSMA-inhibitors based on the same lysine-urea-
glutamate scaffold, and stability of these probes was considered suitable for clinical 
translation [12]. 
Both [68Ga]4 and [64Cu]4 exhibited rapid blood pool clearance and renal excretion. 
Corresponding activity levels in the kidneys declined from 4.39% IA g-1 at 30 min p.i. to 
0.88% IA g-1 after 3 h for [68Ga]4, and from 3.31% IA g-1 at 30 min p.i. to 1.05% IA g-1 after 
3 h for [64Cu]4 (Figure 2A+C). Both compounds showed much lower kidney accumulation 
and faster washout compared to [68Ga]Ga-PSMA-HBED-CC and [68Ga]Ga-PSMA-617, 
consistent with their lower affinity for PSMA [46, 56]. In corresponding blocking studies, the 
kidney uptake was significantly reduced for [68Ga]4, whereas only a slight decrease was 
noted for [64Cu]4 (Figure 2B+D). Despite the low affinity of both tracers for PSMA, the low 
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accumulation and retention of [68Ga]4 and [64Cu]4 in the kidneys is still noteworthy. In 
previous PET imaging studies of our 64Cu-labelled trisubstituted chelators (in absence of a 
targeting vector), we found high uptake in the liver (~11–17% IA g-1) and the kidneys (~20–
40% IA g-1) at 1 h p.i. for the imidazole-type ligands, respectively [57]. It remained unclear 
whether the uptake in liver and kidneys was a result of the positive charge or due to 
demetallation/transchelation. The data of the current PET imaging study shows that the 
biodistribution of both radiotracers is mainly determined by the PSMA targeting vector rather 
than the positive overall charge of the metal chelates and that rapid clearance and low uptake 
in background organs is consistent with kinetically stable metal chelates. 
3.5.2. Ex vivo biodistribution
In addition to the PET imaging studies, we also assayed the pharmacokinetics and the 
stability of [68Ga]4 and [64Cu]4 by ex vivo biodistribution studies (Table 2). Corresponding 
results of selected organs at 1 h p.i. are summarized in Figure 3. In general, results follow the 
same trend as seen in the PET imaging experiments, however, absolute uptake values 
obtained from ex vivo biodistribution studies were slightly higher than those calculated from 
the PET imaging data.  Uptake of [68Ga]4 was low in all organs with < 1% IA g-1 at 1 h p.i. 
with exception of the kidneys, which are known to express PSMA [74]. For [64Cu]4, low but 
overall higher accumulation compared to that of [68Ga]4 was noted in the kidneys, liver, lung 
and intestine. The kidney uptake for [68Ga]4 and [64Cu]4 with 6.28% IA g-1 and 4.96% IA g-1 
was significantly lower than that reported for [68Ga]Ga-PSMA-HBED-CC and [68Ga]Ga-
PSMA-617 with 139.4% IA g-1 and 113.3% IA g-1, respectively [46, 56, 61]. Accumulation in 
the kidneys was PSMA-specific and could be reduced by co-injection of PMPA by ~80% and 
~72% for [68Ga]4 and [64Cu]4, respectively (Table 2). Liver uptake of [64Cu]4 was higher 
than that of [68Ga]4 but was reduced by almost 50% after co-injection of PMPA. Compared 
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to [68Ga]Ga-PSMA-HBED-CC (0.87% IA g-1) and [68Ga]Ga-PSMA-617 (1.17% IA g-1) [46, 
61], liver accumulation was lower for [68Ga]4 (0.30% IA g-1), while it was about two-fold 
higher for [64Cu]4 (2.69 % IA g-1). Nevertheless, this rather low value is not indicative of 
complex instability and substantial transchelation in vivo.  
Tumor accumulation of [68Ga]4 with 1.33% IA g-1 was lower than that of [64Cu]4 with 
2.15% IA g-1. In comparison to [68Ga]Ga-PSMA-HBED-CC and [68Ga]Ga-PSMA-617, which 
have reported tumor uptake of 7.70 and 8.47% IA g-1 [46, 61], respectively, [68Ga]4 and 
[64Cu]4 exhibited lower accumulation in the tumor. This is in line with the lower PSMA 
binding affinity of our NODIA-Me based PSMA targeting probes compared to [68Ga]Ga-
PSMA-HBED-CC and [68Ga]Ga-PSMA-617 [55-56, 61]. A promising strategy for 
improvement of binding affinity and tumor targeting properties may be the addition of 
pendant carboxylic acids to the imidazole-groups of the NODIA-Me chelating moiety, as 
these negatively charged functional groups were reported to lead to additional PSMA binding 
interactions for a series of similar imidazole-containing PSMA targeting probes (vide supra) 
[71]. PSMA specificity of [68Ga]4 and [64Cu]4 was confirmed by co-injection of PMPA 
resulting in reduction of tumor uptake by ~88% and ~70%, respectively. Interestingly, the 
relatively low kidney accumulation and retention of [68Ga]4 and [64Cu]4 resulted in 
significantly improved tumor-to-kidney ratios of 0.21 and 0.43, respectively. These values 
are ~3-8fold higher than those of [68Ga]Ga-PSMA-HBED-CC and [68Ga]Ga-PSMA-617 with 
0.055 and 0.074 [46, 56, 61]. 
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4. Conclusions
In the present work, the novel chelator NODIA-Me 1 was conjugated to the PSMA targeting 
Glu-NH-CO-NH-Lys moiety to give the final bioconjugate 4, which was labelled with 
gallium-68 and copper-64 in molar activities of ~20 MBq nmol-1. The metal-free as well as 
the Ga and Cu complexes of 4 revealed different affinities to PSMA in competitive binding 
studies underscoring the influence of the metal chelate on biological properties. Evaluation of 
the 68Ga- and 64Cu-labelled conjugates by PET imaging and ex vivo biodistribution studies 
demonstrated PSMA-specific tumor uptake. Both compounds exhibited low kidney uptake, 
rapid renal clearance, and only low uptake in non-target organs. Liver accumulation was very 
low for [68Ga]4, while it was moderately increased for [64Cu]4, which could be either due to 
the higher lipophilicity of the 64Cu-complex or suggest a very limited level of transchelation. 
Strategies towards further improvement of binding affinity and tumor targeting of the 
NODIA-Me based PSMA-binding probes may include introduction of additional negative 
charges in the chelating unit by functionalization of the imidazoles with pendant carboxylic 
acid arms and optimization of the spacer moiety. Overall, the results indicate that imidazole-
based TACN chelators show promise for the future development of 68Ga- and 64Cu-labelled 
radiopharmaceuticals. 
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Figure and Scheme Legends
Scheme 1. Selected chelators for copper-64 and gallium-68.
Scheme 2. Synthesis of PSMA targeting conjugate 4. i) HATU, DIPEA, DMF, r.t., 70%; ii) 5 
M HCl, r.t., 91%.
Figure 1. Representative maximum intensity projections (MIPs) of (A) [68Ga]4 and (C) 
[64Cu]4 at 1 h p.i. in LNCaP tumor bearing mice. Blocking studies confirmed the specificity 
of (B) [68Ga]4 and (D) [64Cu]4 for PSMA expression. White arrows indicate organs of 
interest: T = tumor, K = kidney, L = liver.
Figure 2. Bar diagram of the volume-of-interest (VOI) analysis for (A) [68Ga]4 and (C) 
[64Cu]4 in the tumor, the liver, and the kidneys from 30 min – 3 h post administration. 
Corresponding VOI analysis after co-injection of PSMA blocking agent (PMPA) for (B) 
[68Ga]4 and (D) [64Cu]4. For [64Cu]4, data is also provided for 24 h p.i. Legend applies for 
charts A-D.
Figure 3. Ex vivo biodistribution of [68Ga]4 and [64Cu]4 for selected organs in LNCaP tumor 
bearing mice at 1 h p.i along with blocking studies. Data are expressed as %IA g-1 and 
represent mean ± SD (n = 5). 
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Table 1. Analytical data of prepared compounds.
Compound Mass calc. Mass found
HPLCUV/vis
tR [min]
HPLCrad
tR [min] d)
Log Doct/PBS
IC50
[nM]
[nat/68Ga]4 1053.4432a) 1053.4426 15:33 15:50 -4.27 ± 0.08 176 ± 10
[nat/64Cu]4 1048.4550b) 1048.4551 17:42 17:43 -3.99 ± 0.05 681 ± 7 
a) [M – 2H]+ = [C49H68N12O10Ga]+, b) [M – H]+ = [C49H69N12O10Cu]+, UV/vis and 
radioactivity detector in series.
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Table 2. Ex vivo biodistribution of [68Ga]4 and [64Cu]4 in mice bearing PSMA-positive 
LNCaP tumors at 1 h p.i along with blocking studies. Data are expressed as %IA g-1 and 
represent mean ± SD (n = 5).
[68Ga]-4 [64Cu]-4
1 h 1 h blockade 1 h 1 h blockade
blood 0.37 ± 0.15 0.31 ± 0.16 0.31 ± 0.07 0.16 ± 0.01
heart 0.17 ± 0.06 0.15 ± 0.08 0.45 ± 0.09 0.27 ± 0.04
lung 0.50 ± 0.13 0.29 ± 0.08 1.22 ± 0.56 0.49 ± 0.07
spleen 0.46 ± 0.44 0.13 ± 0.04 0.49 ± 0.05 0.21 ± 0.05
liver 0.30 ± 0.22 0.19 ± 0.02 2.69 ± 0.64 1.48 ± 0.27
pancreas 0.17 ± 0.10 0.11 ± 0.05 0.26 ± 0.01 0.14 ± 0.03
stomach 0.30 ± 0.39 0.13 ± 0.08 0.49 ± 0.22 0.25 ± 0.19
intestine 0.34 ± 0.20 0.20 ± 0.15 1.05 ± 0.10 0.83 ± 0.35
kidney 6.28 ± 0.92 1.25 ± 0.23 4.96 ± 0.79 1.39 ± 0.05
muscle 0.16 ± 0.16 0.14 ± 0.11 0.19 ± 0.01 0.62 ± 0.39
bone 0.21 ± 0.23 0.14 ± 0.04 0.19 ± 0.03 0.33 ± 0.28
tumor 1.33 ± 0.46 0.17 ± 0.13 2.15 ± 0.38 0.65 ± 0.04
tumor:blood 3.59 6.32
tumor:kidney 0.21 0.43
tumor:liver 4.43 0.80
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NMR characterization
Figure S1. 1H-NMR spectrum of compound 4 in D2O (pD ≤ 2).
Figure S2. 13C-NMR of compound 4 in D2O (pD ≤ 2)
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Mass spectrometry
Figure S3. LR-ESI(+)-mass spectrum of 2. 
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Figure S4. HR-ESI(+)-mass spectrum of 2. Calc. for [M+H]+ = [C43H68N5O9]+ = 798.5012.
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Figure S5. LR-ESI(+)-mass spectrum of 3. 
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Figure S6. HR-ESI(+)-mass spectrum of 3. Calc. for [M+H]+ = [C61H95N12O10]+ = 1155.7289.
- tBu
- 2 tBu
- 3 tBu
Page S6
Figure S7. LR-ESI(+)-mass spectrum of 4. 
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Figure S8. HR-ESI(+)-mass spectrum of 4. Calc. for [M+H]+ = [C49H71N12O10]+ = 987.5411.
Page S7
D:\data_2018\klind27s_hr05 2/9/2018 1:49:26 PM Ga.nodia.me.naui.ahx.psma
klind27s_hr05 #1 RT: 0.00 AV: 1 NL: 1.49E7
T: FTMS + p ESI Full lock ms [100.00-2000.00]
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
Ab
un
da
nc
e
1053.4426
1055.4429
528.5118
506.5299
529.5151
906.3911304.2614 1075.4249880.4109 908.3902 1077.4243453.6981
Figure S9. HR-ESI(+)-mass spectrum of Ga-4. Calc. for [M – 2H]+ = [C49H68N12O10Ga]+ = 
1053.4432.
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Figure S10. HR-ESI(+)-mass spectrum of Cu-4. Calc. for [M – H]+ = [C49H69N12O10Cu]+ = 
1048.4550. 
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HPLC chromatography
Figure S11. UV/vis trace of HPLC chromatogram of 4.
Figure S12. UV/vis trace of HPLC chromatogram of Ga-4.
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Figure S13. Radioactivity trace of HPLC chromatogram of [68Ga]4.
Figure S14. Radio-HPLC chromatogram of [68Ga]4 after 4 h incubation in human serum.
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Figure S15. UV/vis trace of HPLC chromatogram of Cu-4.
Figure S16. Radioactivity trace of HPLC chromatogram of [64Cu]4.
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Figure S17. Radio-HPLC chromatogram of [64Cu]4 after 24 h incubation in human serum.
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Figure S18. Determination of binding affinity of compounds 4, Ga-4 and Cu-4 by competitive 
titration on LNCaP cells using [68Ga]Ga-PSMA-HBED-CC as radioligand.
